liver disease – Medxy AI

Elafibranor Shows Promise as a Safe and Effective Therapy for Primary Sclerosing Cholangitis: Insights from the Phase II ELMWOOD Trial

By MedXY 10/29/2025

The phase II ELMWOOD trial demonstrates that elafibranor, a dual PPAR-α/δ agonist, is well tolerated and significantly improves biochemical markers in patients with primary sclerosing cholangitis over 12 weeks, warranting further investigation.

Gastroenterology Internal Medicine news

Persistent High Mortality in Severe Alcohol-Associated Hepatitis: Insights from a Five-Decade Meta-Analysis

By MedXY 10/09/2025

This meta-analysis reveals that short-term mortality in severe alcohol-associated hepatitis remains high, with no significant improvement over the past four decades despite advances in care, underscoring the urgent need for better therapies and prognostic strategies.

Family Medicine & Nutrition news Specialties

Seven Groups Who Should Avoid Fish Oil: Essential Precautions You Must Know

By MedXY 08/08/2025

Fish oil offers health benefits but is not suitable for everyone. Learn about the seven groups who should avoid fish oil to prevent health risks and ensure safe supplement use.

Diabetes & Endocrinology news Pediatrics Specialties

Severe Childhood Obesity Linked to Elevated Health Risks

By MedXY 07/25/2025

A new study highlights the growing prevalence of extreme pediatric obesity in the U.S. and its association with serious metabolic and cardiovascular health risks, emphasizing the need for targeted interventions.